|
References
- Xing L., Wessels B., & Hendee, W. (2005). Point-counter-point debate: The value of PET/CT is being oversold as a clinical tool in radiation oncology. Medical Physics, 32, 1457-8.
- Kresnik, E., Mikosch, P., Gallowitsch, H.J., Kogler, D., et al. (2001). Evaluation of head and neck cancer with 18F-FDG PET: A comparison with conventional methods. Eur J Nucl Med, 28, 816-21.
- Dizendorf, E.V., Baumert, B.G., von Schulthess, G.K., Lutolf, U.M., et al. (2003). Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med, 44, 24-9.
- Kitagawa, Y., Sano, K., Nishizawa, S., Nakamura, M., et al. (2003). FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med, 30, 63-71.
- Lardinois, D., Weder, W., Hany, T.F., Kamel, E.M., et al. (2003). Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med, 348, 2500-7.
- Bruzzi, J.F., & Munden, R.F. (2006). PET/CT imaging of lung cancer. J Thorac Imaging, 21, 123-36.
- Jhanwar, Y.S., & Straus, D.J. (2006). The role of PET in lymphoma. J Nucl Med, 47, 1326-34.
- Buck, A.K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., et al. (2002). 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res, 62, 3331-4.
- Rajendran, J.G. & Krohn, K.A. (2005). Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am, 43.
- Beer, A.J., Haubner, R., Sarbia, M., Goebel, M., et al. (2006). Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res, 12, 3942-9.
- Jacobs, A.H., Rueger, M.A., Winkeler, A., Li, H., et al. (2007). Imaging-guided gene therapy of experimental gliomas. Cancer Res, 67, 1706-15.
|